Published in TB and Outbreaks Week, July 13th, 1998
The product, palivizumab, is a genetically engineered antibody against the RSV virus. This antibody is manufactured using human and mouse antibody genes and can be produced consistently on a large scale.
Palivizumab is the second product licensed for RSV disease. The first one, RSV Immune Globulin Intravenous (Human) (RSVIGIV) is made from human plasma and is marketed as RespiGam by MedImmune Inc,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.